share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Prasad Raju

SEC announcement ·  Mar 19 05:46
Summary by Futu AI
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG (CRSP), completed a sale of 3,524 shares of common stock on March 15, 2024. The transaction was executed at a price of $72.69 per share, resulting in a total market value of $256,159.56. This sale followed an acquisition of 10,000 shares on March 14, 2024, through the exercise of derivative securities. After these transactions, Prasad's direct holdings in the company amount to 6,476 shares of common stock.
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG (CRSP), completed a sale of 3,524 shares of common stock on March 15, 2024. The transaction was executed at a price of $72.69 per share, resulting in a total market value of $256,159.56. This sale followed an acquisition of 10,000 shares on March 14, 2024, through the exercise of derivative securities. After these transactions, Prasad's direct holdings in the company amount to 6,476 shares of common stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.